{"id":631,"date":"2021-07-07T13:16:58","date_gmt":"2021-07-07T13:16:58","guid":{"rendered":"https:\/\/covispharma.com\/?page_id=631"},"modified":"2022-02-23T12:45:18","modified_gmt":"2022-02-23T12:45:18","slug":"timeline","status":"publish","type":"page","link":"https:\/\/covispharma.com\/index.php\/timeline\/","title":{"rendered":"Timeline"},"content":{"rendered":"

[et_pb_section fb_built=”1″ custom_padding_last_edited=”on|phone” module_id=”news” _builder_version=”4.14.8″ _module_preset=”default” background_color=”#2d81b5″ custom_margin=”||||false|false” custom_padding=”2.5rem||5px||false|false” custom_padding_tablet=”||||false|false” custom_padding_phone=”1.5rem||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.9.7″ _module_preset=”default” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.9.7″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” header_font=”|600|||||||” header_text_color=”#FFFFFF” header_font_size=”3rem” header_line_height=”3.5rem” header_font_size_tablet=”2rem” header_font_size_phone=”” header_font_size_last_edited=”on|tablet” header_line_height_tablet=”2.5rem” header_line_height_phone=”” header_line_height_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n

Historic Milestones<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.7″ _module_preset=”default” custom_padding=”0px||20px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.9.7″ _module_preset=”default” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.9.7″ _module_preset=”default” global_colors_info=”{}”][et_pb_code disabled_on=”off|off|off” _builder_version=”4.14.8″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] <\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2022<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

January 2022<\/h3>\n

Covis Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2020<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

November 2020<\/h3>\n

Covis Group completes acquisition of AMAG Pharmaceuticals along with the global rights for Makena\u00ae and Feraheme\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

February 2020<\/h3>\n

Funds managed by affiliates of Apollo Global Management acquired Covis Pharma from Cerberus.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2018<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

November 2018<\/h3>\n

Acquired global rights for Alvesco\u00ae, Omnaris\u00ae, and Zetonna\u00ae.<\/pee><\/div>\n<\/p><\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2017<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

July 2017<\/h3>\n

Acquired the U.S. marketing and distribution rights for Alvesco\u00ae, Omnaris\u00ae, and Zetonna\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

April 2017<\/h3>\n

Acquired the U.S. marketing and distribution rights for Prilosec\u00ae Packets.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2016<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

November 2016<\/h3>\n

Acquired the U.S. marketing and distribution rights for Sular\u00ae.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2015<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

May 2015<\/h3>\n

Acquired the U.S. marketing and distribution rights for Altoprev\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

April 2015<\/h3>\n

Divested majority of product assets to Concordia Healthcare Corp in a deal valued at $1.2 billion.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

January 2015<\/h3>\n

Acquired the U.S. marketing and distribution rights for Betapace\u00ae & Betapace AF\u00ae.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2014<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

October 2014<\/h3>\n

Acquired the U.S. marketing and distribution rights for Dibenzyline\u00ae and Dyrenium\u00ae.Entered into authorized generic agreement with Prasco for several brands.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

February 2014<\/h3>\n

Acquired the U.S. marketing and distribution rights for DuToprol\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

January 2014<\/h3>\n

Initiated funding of cardiology sales force for U.S. distribution partner to promote Lanoxin\u00ae.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2013<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

December 2013<\/h3>\n

Entered into authorized generic agreement with Par Pharmaceuticals for Lanoxin\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

October 2013<\/h3>\n

Received FDA approval for the alternative dosage strengths of Lanoxin\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

June 2013<\/h3>\n

Entered into authorized generic agreement with Rising Pharmaceuticals for Rilutek\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

April 2013<\/h3>\n

Acquired the U.S. marketing and distribution rights for Kayexalate\u00ae, Nilandron\u00ae, Plaquenil\u00ae, Rilutek\u00ae, and Uroxatral\u00ae from Sanofi.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2012<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

October 2012<\/h3>\n

Entered into authorized generic agreement with Rising Pharmaceuticals for Parnate\u00ae.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

January 2012<\/h3>\n

Initiated development of alternative dosage strengths of Lanoxin\u00ae.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n
<\/p>\n
<\/div>\n

<\/p>\n

2011<\/h2>\n

<\/div>\n

<\/div>\n

<\/p>\n

<\/p>\n
<\/p>\n

December 2011<\/h3>\n

Acquired the U.S. marketing and distribution rights for Lanoxin\u00ae, Lanoxin\u00ae IV Parnate\u00ae, Zantac\u00ae, Fortaz\u00ae and Zinacef\u00ae from GlaxoSmithKline.<\/pee><\/div>\n

<\/p>\n

<\/p>\n

April 2011<\/h3>\n

Founded by Cerberus Capital Management, the investment management firm with over $30 billion in assets under management.<\/pee><\/div>\n

<\/div>\n

<\/p>\n

<\/div>\n

<\/div>\n

<\/html> <\/p>\n